Pipeline

Despite significant advances in oncology, there is still a large unmet need in treating patients with solid tumors, especially those with advanced disease. Our approach begins with our proprietary computational discovery platform to identify new drug targets and biological pathways that could enhance anti-cancer immune responses. With these new targets in hand and a deep understanding of their underlying biology, we are advancing new therapeutics and optimizing their combination to expand immuno-oncology treatment options to cancer patients who are not responsive to currently available drugs.